目的:CLEC10A在多种细胞中表达,参与多种生物学途径,包括免疫反应,与肿瘤免疫反应的发生发展密切相关。然而,从泛癌症的角度来看,CLEC10A的作用尚未得到分析,其在人类癌症预后和免疫学中的作用仍不清楚。
方法:我们研究了CLEC10A的表达水平,并研究了其在不同数据集(包括Oncomine,cBioPortal,和TCGA,并使用新鲜的膀胱癌和乳腺癌样本进行免疫组织化学实验以验证结果。此外,我们还对CLEC10A进行了GSEA,并探讨了CLEC10A表达与免疫浸润之间的关系,免疫检查点,免疫激活基因,免疫抑制基因,趋化因子和趋化因子受体。
结果:结果显示,与非癌组织相比,大多数肿瘤中CLEC10A的表达水平显着降低,表达下降与预后差和晚期癌症分期有关。我们还发现CLEC10A的表达与淋巴和非淋巴细胞之间的免疫调节相互作用显着相关。此外,CLEC10A的表达不仅与CD4+T细胞和CD8+T细胞的浸润水平显著相关,但也与免疫检查点密切相关,免疫激活基因,免疫抑制基因,趋化因子,和趋化因子受体.重要的是,我们对CLEC10A与TMB和MSI之间关系的分析也证实了CLEC10A可能通过调节肿瘤微环境的组成和免疫机制来影响抗肿瘤免疫的推测。
结论:结论:CLEC10A可作为肿瘤免疫治疗的新靶点,作为预测泛癌症预后和免疫浸润的分子生物标志物具有巨大潜力。
OBJECTIVE: CLEC10A is expressed in a variety of cells, involved in a variety of biological pathways including immune response, and is closely related to the development of tumor immune response. However, the role of
CLEC10A from a pan-cancer perspective has not yet been analyzed, and its role in human cancer prognosis and immunology remains largely unclear.
METHODS: We studied the expression levels of
CLEC10A and investigated its prognostic value in various cancers across distinct datasets including Oncomine, cBioPortal, and TCGA, and conducted immunohistochemical experiments using fresh bladder cancer and breast cancer samples to verify the results. In addition, we also performed GSEA of
CLEC10A and explored the relationship between
CLEC10A expression and immune infiltration, immune checkpoints, immune activation genes, immunosuppressive genes, chemokines and chemokine receptors.
RESULTS: The results showed that the expression level of CLEC10A in most tumors was significantly lower compared with non-cancerous tissue, and the decreased expression was related to poor prognosis and more advanced cancer stages. We also found that the expression of CLEC10A was significantly related to the immunomodulatory interaction between lymph and non-lymphocytes. Furthermore, the expression of CLEC10A was not only significantly correlated with the level of infiltration of CD4+T cells and CD8+T cells, but also closely related to immune checkpoints, immune activation genes, immunosuppressive genes, chemokines, and chemokine receptors. Importantly, our analysis of the relationship between CLEC10A and TMB and MSI also confirmed the speculation that
CLEC10A may influence antitumor immunity by regulating the composition and immune mechanisms of the tumor microenvironment.
CONCLUSIONS: In conclusion, CLEC10A may serve as a new target for tumor immunotherapy and has great potential as a molecular biomarker for predicting pan-cancer prognosis and immune infiltration.